# NIH Reporter #3U01NS110772-05S3

FVIIa for Acute hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial

**Recipient:** University of Cincinnati, Neurology

**Award Amount:** $50,000.00
**Ceiling:** $50,000.00

**Awarded:** March 05, 2026

**Identifier:** 3U01NS110772-05S3

The NIH-funded FASTEST Trial evaluates whether administering recombinant Factor VIIa within two hours of spontaneous intracerebral hemorrhage improves 90-day functional outcomes compared with placebo.

### Description

A randomized, double-blind, controlled global trial testing recombinant Factor VIIa plus best standard therapy versus best standard therapy alone for patients with intracerebral hemorrhage.

[View original record](https://reporter.nih.gov/search/7RZVnLFgNEWpofIHyjL5uw/project-details/11473255)